{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:17:59Z","timestamp":1740115079100,"version":"3.37.3"},"reference-count":36,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005622","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-EX105-10228PC"],"award-info":[{"award-number":["NHRI-EX105-10228PC"]}],"id":[{"id":"10.13039\/100005622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.vaccine.2018.08.019","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T20:41:56Z","timestamp":1534970516000},"page":"5902-5909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Modelling the effect of discontinuing universal Bacillus Calmette-Gu\u00e9rin vaccination in an intermediate tuberculosis burden setting"],"prefix":"10.1016","volume":"36","author":[{"given":"Han","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsien-Ho","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy B.","family":"Hallett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimalan","family":"Arinaminpathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.08.019_b0005","first-page":"53","article-title":"History of BCG vaccine","volume":"8","author":"Luca","year":"2013","journal-title":"Maedica (Buchar)."},{"key":"10.1016\/j.vaccine.2018.08.019_b0010","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/cid\/cit790","article-title":"Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials","volume":"58","author":"Mangtani","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.08.019_b0015","first-page":"27","article-title":"BCG vaccine. WHO position paper","volume":"79","author":"World Health Organization","year":"2004","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2018.08.019_b0020","doi-asserted-by":"crossref","unstructured":"Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease. Tubercle and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 1994;75:179\u201380.","DOI":"10.1016\/0962-8479(94)90003-5"},{"key":"10.1016\/j.vaccine.2018.08.019_b0025","doi-asserted-by":"crossref","unstructured":"Infuso A, Falzon D, Euro TBn. European survey of BCG vaccination policies and surveillance in children, 2005. Euro Surveill. 2006;11:6\u201311.","DOI":"10.2807\/esm.11.03.00604-en"},{"key":"10.1016\/j.vaccine.2018.08.019_b0030","article-title":"The transmission dynamics of tuberculosis in a recently developed Chinese city","volume":"5","author":"Wu","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.08.019_b0035","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S0950268897007917","article-title":"The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection","volume":"119","author":"Vynnycky","year":"1997","journal-title":"Epidemiol Infect"},{"issue":"1\u2013372","key":"10.1016\/j.vaccine.2018.08.019_b0040","first-page":"v","article-title":"Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis","volume":"17","author":"Abubakar","year":"2013","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.vaccine.2018.08.019_b0045","unstructured":"External review of \u201cHalving TB in 10 years program in Taiwan, 2006\u20132015\u201d. Taiwan: Taiwan Center for Disease Control; 2014."},{"key":"10.1016\/j.vaccine.2018.08.019_b0050","unstructured":"Taiwan Centers for Disease Control. Taiwan National Infectious Disease Statistics System; 2005-2016."},{"key":"10.1016\/j.vaccine.2018.08.019_b0055","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3201\/eid2103.140789","article-title":"Mycobacterium bovis BCG-associated osteomyelitis\/osteitis, Taiwan","volume":"21","author":"Chiu","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.08.019_b0060","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/cir951","article-title":"Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis","volume":"54","author":"Andrews","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.08.019_b0065","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1137\/140956695","article-title":"Epidemiological consequences of imperfect vaccines for immunizing infections","volume":"74","author":"Magpantay","year":"2014","journal-title":"SIAM J Appl Math"},{"key":"10.1016\/j.vaccine.2018.08.019_b0070","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g4643","article-title":"Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis","volume":"349","author":"Roy","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2018.08.019_b0075","unstructured":"Taiwan Department of Household Registration. Population Statistics; 1906-2016."},{"key":"10.1016\/j.vaccine.2018.08.019_b0080","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1016\/S2214-109X(15)00069-8","article-title":"Disability weights for the Global Burden of Disease 2013 study","volume":"3","author":"Salomon","year":"2015","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2018.08.019_b0085","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1016\/j.vaccine.2015.07.039","article-title":"Management of Bacillus Calmette-Guerin osteomyelitis\/osteitis in immunocompetent children \u2013 a systematic review","volume":"33","author":"Lin","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.019_b0090","first-page":"4","article-title":"BCG-induced osteomyelitis\/osteitis cases","volume":"60","author":"Chiu","year":"2017","journal-title":"Taiwan Med J"},{"key":"10.1016\/j.vaccine.2018.08.019_b0095","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/annrheumdis-2013-204344","article-title":"The global burden of musculoskeletal conditions for 2010: an overview of methods","volume":"73","author":"Hoy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2018.08.019_b0100","unstructured":"Taiwan National Health Insurance Administration. Taiwan National Health Insurance Database for Drugs, 2017."},{"key":"10.1016\/j.vaccine.2018.08.019_b0105","unstructured":"Taiwan National Health Insurance Administration. Taiwan National Helath Insurance Database for Medical Procedures, 2017."},{"key":"10.1016\/j.vaccine.2018.08.019_b0110","unstructured":"Taiwan Centers for Disease Control. Budget for Immunization Programs, 2017."},{"key":"10.1016\/j.vaccine.2018.08.019_b0115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13690-016-0141-0","article-title":"Evaluating the neonatal BCG vaccination programme in Ireland","volume":"74","author":"Usher","year":"2016","journal-title":"Arch Public Health"},{"key":"10.1016\/j.vaccine.2018.08.019_b0120","doi-asserted-by":"crossref","first-page":"15520","DOI":"10.1073\/pnas.1404386111","article-title":"Impact and cost-effectiveness of new tuberculosis vaccines in low-and middle-income countries","volume":"111","author":"Knight","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2018.08.019_b0125","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2458-11-55","article-title":"Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study","volume":"11","author":"Tseng","year":"2011","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2018.08.019_b0130","doi-asserted-by":"crossref","unstructured":"Keeling MJ, Rohani P. Modeling infectious diseases in humans and animals. Princeton, NJ: Princeton University Press; 2008.","DOI":"10.1515\/9781400841035"},{"key":"10.1016\/j.vaccine.2018.08.019_b0135","first-page":"5","article-title":"The rise, critique and persistence of the DALY in global health","volume":"4","author":"Parks","year":"2014","journal-title":"J Global Health"},{"key":"10.1016\/j.vaccine.2018.08.019_b0140","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1586\/erv.09.161","article-title":"BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control","volume":"9","author":"Merle","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.08.019_b0145","article-title":"Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review","volume":"355","author":"Higgins","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2018.08.019_b0150","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1016\/j.vaccine.2013.03.059","article-title":"Non-specific effect of Bacille Calmette-Guerin vaccine on the immune response to routine immunisations","volume":"31","author":"Ritz","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.08.019_b0155","first-page":"22","article-title":"A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guerin in Finland","volume":"7","author":"Hersh","year":"2003","journal-title":"Int J Tuberc Lung Disease Off J Int Union Against Tuberculosis Lung Disease"},{"key":"10.1016\/j.vaccine.2018.08.019_b0160","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0041-3879(83)90034-X","article-title":"Childhood tuberculosis in Sweden. An epidemiological study made six years after the cessation of general BCG vaccination of the newborn","volume":"64","author":"Romanus","year":"1983","journal-title":"Tubercle"},{"key":"10.1016\/j.vaccine.2018.08.019_b0165","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1164\/ajrccm.162.4.9911106","article-title":"Risk of tuberculosis infection and tuberculous meningitis after discontinuation of Bacillus Calmette-Guerin in Beijing","volume":"162","author":"Zhang","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.vaccine.2018.08.019_b0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jech.43.1.15","article-title":"The effects of the scheme for BCG vaccination of schoolchildren in England and Wales and the consequences of discontinuing the scheme at various dates","volume":"43","author":"Sutherland","year":"1989","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.vaccine.2018.08.019_b0175","first-page":"32","article-title":"First experience with BCG discontinuation in Europe. Experience in Sweden 15 years after stopping general BCG vaccination at birth","volume":"65","author":"Romanus","year":"1990","journal-title":"Bull Int Union Tuberc Lung Dis"},{"key":"10.1016\/j.vaccine.2018.08.019_b0180","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0041-3879(76)90015-5","article-title":"Impact of BCG vaccination programmes in children and young adults on the tuberculosis problem","volume":"57","author":"Styblo","year":"1976","journal-title":"Tubercle"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18311289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18311289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T11:08:13Z","timestamp":1717240093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18311289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":36,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0264410X18311289"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.08.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling the effect of discontinuing universal Bacillus Calmette-Gu\u00e9rin vaccination in an intermediate tuberculosis burden setting","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}